
    
      Prospective, multicenter, 2:1 randomized, cross-over, two arms

        -  Control arm: Double-dose PPI [Omeprazole 20 mg BID (twice a day)]

        -  Treatment arm: LINX Reflux Management System Up to 20 study centers throughout the U.S.
           will participate. Approximately150 patients will be enrolled into the study. Subjects
           will be randomized 2:1 into the double-dose PPIs arm (100 subjects) and the LINX arm (50
           subjects).
    
  